Status:
COMPLETED
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects
Eligibility Criteria
Inclusion
- Healthy men and women of non-childbearing potential between the ages of 18 and 50.
- Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg2.
- Have a high probability for compliance with and completion of the study.
Exclusion
- Presence or history of any disorder that may prevent the successful completion of the study.
- Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00722501
Start Date
August 1 2008
End Date
November 1 2008
Last Update
April 28 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Trial Manager
Philadelphia, Pennsylvania, United States, 19148